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P03.111 ATOMOXETINE AND CORTICAL ACTIVITY IN ADULTS
WITH ADHD
M. Adamou1, W. Plummer2, I. Maidment2, V. Mirtsou-Fidani3, A. Hale4. 1Kent
Institute of Medicine and Health Sciences, UK; 2Kent and Medway NHS and
Social Care Partnership Trust, UK; 3Laboratory of Pharmacology, Aristotle
University of Thessaloniki, Greece; 4University of Kent, UK
Background: The neuropsychological functioning of individuals with ADHD
has been extensively studied in childhood but not as well in adults. Although
the neuropsychological functioning of adults with ADHD has been studied, the
quality, quantity and strength of these data are only conclusive in specific areas
of functioning such as working memory and response inhibition but not as to the
effects of treatment in the neuropsychological functioning of adults with ADHD.
Aims: To assess the effect of a licensed treatment for Adults with ADHD in
the neuropsychological functioning of Adults with ADHD.
Methods: We measured the severity of symptoms of patients with a diagnosis
of Adult ADHD using the Conners’ Adult ADHD Rating Scale (CAARS) and
changes in the integrative capacity of their central nervous system by measuring
changes in their Critical Flicker Fusion (CFF) threshold. Two measurements
were taken, one at baseline and a second four weeks later after treatment with
80 mg/daily with the norandrenaline uptake inhibitor atomoxetine. The CAARS
was measured by the same trained investigator.
Results: There was no significant change in the CFF threshold before and
after treatment with atomoxetine in 4 weeks (mean before: 33.85 Hz, mean after:
33.89 Hz, p = 0.98). There was a reduction of 21.6 units in CAARS, which is
statistically significant (mean before: 39, mean after: 17.4, p = 0.004).
Conclusions: Atomoxetine is a clinically efficacious treatment for adults with
ADHD with four weeks of treatment. This effect is delivered without affecting
cortical activity, and this is reflected in its mechanism of action. The speed of
processing and the integrative capacity of the central nervous system do not
seem to be affected by atomoxetine despite statistically and clinically clinical
improvement. Improvement of ADHD symptomatology may not be related to
cortical activity and more specific tests of assessing cortical functioning may
produce better results.
P03.112 EVALUATION OF TREATMENT OUTCOMES OF KEPPRA
(LEVETIRACETAM) IN PEDIATRIC SEIZURES
A. Omrani. NanoMedical Studies Group, Iran
The Food and Drug Administration (FDA) approved Levetiracetam on November
1999. Recent studies have demonstrated the utility of Levetiracetam (Keppra)
for treatment of partial seizures in children. Some studies have reported that
Levetiracetem may also be useful in some patients with absence, generalized or
myclonic seizures. According to some reports, Levetiracetam has been considered
as a potential option for children with treatment resistant partial seizures.
In children, according to some recent reports, Levetiracetam should be initiated
at a dose of 10 mg/kg/day divided and given twice daily. The dose may be
increased by 5 to 10 mg/kg/day increment every 2 weeks as needed, up to
40 mg/kg/day. In patients with moderate to severe renal dysfunction, 505, still
given twice daily, should reduce the dose of Levetiracetam.
Some advantages of Levetiracetam over other antiepileptic drugs include
relatively benign adverse effects, no drug interaction with other anticonvulsants,
a wide margin of safety with no requirements of serum drug concentration
monitoring. Keppra appears to have less adverse effects on cognitive function
than traditional drugs.
The most frequent adverse effects in children have been reported to be
anorexia, headache somnolence and adverse neuropsychiatric symptoms includ-
ing agitation, apathy, anxiety, hostility, emotional liability, and depression. Some
adverse effects are seen most frequently in the first month of therapy and typically
lessen or resolve with continued treatment. Based on some studies, the onset of
symptoms ranged from 2 days to 3 months after starting Levetiracetam.
Observations suggest that slower dose titration, beginning at 10 mg/kg/day
and increasing to 20 mg/kg/day over 4 weeks may be beneficial in preventing
some adverse effects, particularly in children predisposed to neuropsychiatric
symptoms.
Levetiracetam has been associated with minor changes in hematologic studies
in patients. Decreases In hemoglobin, red blood cell counts, hematocrit, white
blood cell counts, and neurophil count have been reported in some patients in
premarketing trials.
Patients requiring discontinuation of therapy should have their Levetiracetam
dose slowly tapered over the course of 2−4 weeks to prevent withdrawal seizures.
P03.113 EFFECT OF SUB-CHRONIC TREATMENT WITH
JARSIN® (EXTRACT OF ST JOHN’S WORT, HYPERICUM
PERFORATUM) AT TWO DOSE LEVELS ON EVENING
SALIVARY MELATONIN AND CORTISOL IN HEALTHY
MALE VOLUNTEERS
M. Franklin1, S. Hafizi2, H. Murck3, R. Hockney2, A. Reed2. 1Oxford Brookes
University, UK; 2University of Oxford, UK; 3Litchwer Pharma AG, Germany
Background: Clinical studies have shown that extracts of Hypericum perforatum
(HP) are comparable to antidepressants such as imipramine for mild to moderate
depression and that it exerts its action mainly as a monoamine re-uptake inhibitor.
Our previous studies have shown that HP increases cortisol, growth hormone and
reduces prolactin in plasma. We suggest that these effects are consistent with
facilitation of serotonin (5-HT) and dopamine (DA) but not with noradrenaline
(NA). Objective: The aim of the present study was to measure the effect of two
doses of extracts from HP, Jarsin®, on evening salivary cortisol and NA-mediated
melatonin in healthy volunteers.
Methods: 20 healthy male volunteers were randomly given a low
(2×300 mg/day) or high (2×900 mg/day) dose of Jarsin for 7 days. Saliva
samples for cortisol and melatonin, and overnight urine samples were collected
for cortisol and 6-sulphatoxy-melatonin and measured by radioimmunoassay.
Results: Treatment significantly increased salivary cortisol throughout the
whole collection period in the low dose group but had no discernable effect in
the high dose group. Salivary melatonin was not effected in either dose group.
Conclusion: Salivary cortisol was enhanced in the low dose group only and
melatonin was not affected by either treatment. We suggest that Jarsin may
enhance salivary cortisol via a U-shaped dose-response relationship and that this
may be mediated through a 5-HT2 mechanism.
Acknowledgement: This work was supported by a grant from Litchwer Pharma
AG, Berlin, Germany.
P03.114 ALEXITHYMIA IN VITILIGO AND CHRONIC
URTICARIA PATIENTS: A CONTROLLED STUDY
M. Sukan, F. Maner, K. Sayar. Department of Psychiatry, Bakırko¨y State Teaching
and Research Hospital of Psychiatry and Neurological Sciences, Turkey
Alexithymia is described as a lack of words of feelings; it may be present in
many skin disorders including vitiligo and chronic urticaria.
Methods: 50 vitiligo, 50 chronic urticaria patients were compared with age-
and sex- matched 50 healthy controls to assess alexithymia using Toronto alex-
ithymia Scale-20 (TAS-20). The patient group was recruited from dermatology
clinics at four major hospitals in Istanbul, from February 2003 till December
2004.
Results: The scores for TAS-1 item (difficulty identifying feelings), and TAS-2
item (difficulty describing feelings) were significantly higher in vitiligo and
chronic urticaria groups than controls. The scores for TAS-3 (externally-oriented
thinking) were also statistically higher in vitiligo and chronic urticaria groups
than controls, but the scores for TAS-3 in the chronic urticaria group were higher
than vitiligo group. The total scores of TAS were significantly higher in both of
the patient groups than controls.
Conclusion: There were more alexithymic cases in vitiligo and chronic
urticaria groups than controls. Alexithymia may be a coping mechanism of the
psyche in these skin disorders.
Sayar K, Gu¨lec¸ H, Ak I: The reliability and validity of the Twenty-item
Toronto Alexithymia Scale. 37th National Congress of Psychiatry, Scientific
Studies Abstract Book, Istanbul, 2001:130.
Picardi A, Pasquini P, Cattaruzza MS, Gaetano P, Melchi CF, Baliva G,
Camaioni D, Tiago A, Abeni D, Biondi M: Stressful life events, social support,
attachment security and alexithymia in vitiligo. A case-control study. Psychother
Psychosom 2003; 72: 150–158.
P03.115 EFFECTS OF REGULAR EXERCISE IN THE
PSYCHIATRIC INPATIENT TREATMENT SETTING: A
NATURALISTIC STUDY
F. Ng1, S. Dodd1, M. Berk1, S. Campbell1, F. Jacka1, L. Williams1, E. Leslie3.
1University of Melbourne, Swanston Centre – Barwon Health, Australia;
2The Geelong Clinic, Australia; 3Deakin University, Australia
Objective: The role of physical activity as a therapeutic tool for psychiatric
illness is controversial. Some studies have suggested benefits [1,2]. Physical
activity is associated with additional health benefits, including assisting in weight
control, which is a pertinent issue in a psychiatric population. An optional
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walking activity was introduced at a psychiatric inpatient unit in Geelong,
Australia. The efficacy of the walking program at improving psychiatric outcomes
is assessed in this study.
Methods: Inpatients at a private psychiatric unit were offered the opportunity
to participate in a daily morning 40-minute walk led by an activity supervisor.
The patients were equally encouraged to participate in all group program
activities, which in addition to the walking group, also included art, relaxation,
music and psycho-educational sessions. After discharge, outcomes for patients
who had regularly participated in the walking group (N = 35) and patients who
had not participated (N = 49) were compared for length of stay during their period
of admission, Clinical Global Impression – Severity (CGI-S) and Depression
Anxiety Stress Scales (DASS) scores as measured at admission and discharge.
This was a naturalistic study and had no exclusion criteria or randomisation.
Results: There were no significant differences between the two cohorts on most
primary outcome measures, including length of stay, DASS scores at admission
and at discharge and CGI-S scores at admission. Patients who had not participated
in the walking group had a significantly lower score on a single measure, the
CGI-S, than patients who had participated ( p = 0.001).
Conclusions: This study does not support the hypothesis that participating in
the walking program would result in improvement in the outcomes measured.
However, interpretation of these results have to take into consideration a number
of limitations in study design, such as the small sample size, selection bias relat-
ing to patient variables such as psychiatric diagnosis and physical comorbidities,
lack of variable control and randomisation, and the use of broad outcome mea-
sures. The finding of a significantly higher CGI-S outcome for non-participants of
the walking group is of interest. This may reflect an overriding therapeutic effect
from other measures, such as psychological and pharmacological interventions,
and the other non-exercise-based group activities, or there could be a recruitment
bias where patients with more persistent symptoms are attracted to the walking
group. This study nevertheless suggests that a physical activities program is well
received by patients in the inpatient setting. Randomised, controlled trials of
adequate power are required to determine whether offering a physical activity
program in a psychiatric inpatient facility may be useful.
(1) Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise
treatment for depression: efficacy and dose response. Am J Prev Med 2005;
28(1): 1−8.
(2) Dimeo F, Bauer M, Varahram I, Proest G, Halter U: Benefits from aerobic
exercise in patients with major depression: a pilot study. Br J Sports Med
2001; 35(2): 114−7.
P03.116 ONSET AND OUTCOME; A META-ANALYSIS OF
ESCITALOPRAM TRIALS IN DEPRESSION
S. Kasper1, H. Andersen2, A. Wade3. 1University of Vienna, Austria; 2H. Lund-
beck A/S, Denmark; 3CPS Clinical Research Centre, United Kingdom
Objective: To analyze the importance of early onset of effect for the eventual
treatment outcome and to study the contribution of individual items of the
Montgomery-A˚sberg Depression Rating Scale (MADRS) to the improvement
in the MADRS total score.
Methods: All five published placebo-controlled clinical studies in depression
as per January 1, 2005, with escitalopram, were included in this pooled anal-
ysis [1−5]. The pre-defined primary measure of efficacy was the change from
baseline to final assessment (Week 2 in 1 study) of the MADRS total score.
Onset of effect was defined as 20% reduction of the baseline efficacy score.
Results: Of the 1621 patients who were randomised to either escitalopram
(871) or placebo (750), 1333 completed 8 weeks of treatment (707 escitalopram
and 626 placebo). A statistically significant difference ( p < 0.05) between the
MADRS total score responses of escitalopram and placebo treatments was
observed at Week 1. All ten MADRS single items showed a significant treatment
effect at Week 8. For items representing core symptoms of depression, (1, 2, 3,
6, 9, 10) the effect was detected early (Week 1) and for other items (4, 5, 7)
the effect was detected later (Week 6−8). Of the patients who showed an onset
of effect after two weeks and who remained on escitalopram until Week 8, 63%
were in remission at Week 8 (mean MADRS total score of 6.1).
Conclusions: Onset of treatment response at 2 weeks is an important indicator
of subsequent remission at 8 weeks. If patients fail to show a measurable clinical
improvement within 2 weeks (at least a 20% decrease from baseline in MADRS
total score), a dose increase should be considered at this time.
(1) Burke WJ, Gergel I, Bose A (2002). J Clin Psychiatry 63, 331–336.
(2) Lepola UM, Loft H, Reines EH (2003). Int Clin Psychopharmacol 18, 211–
217.
(3) Ninan PT, Ventura D, Wang J (2003). Poster presented at the Congress of
the American Psychiatric Association, May 17−22, San Francisco, CA.
(4) Rapaport MH, Bose A, Zheng H (2004). J Clin Psychiatry 65, 44−49.
(5) Wade A, Lemming OM, Hedegaard KB (2002). Int Clin Psychopharmacol
17, 95–102.
P03.117 POST-MARKETING SURVEILLANCE OF
ESCITALOPRAM IN DEPRESSED OUTPATIENTS
H.-J. Mo¨ller1, K. Lotze2, S. Langer2, S. Montgomery3. 1Psychiatric Department,
Munich University, Germany; 2Lundbeck GmbH, Germany; 3Imperial College,
United Kingdom
Objective: The objective of the current study was to evaluate the efficacy
and tolerability of escitalopram in the treatment of depressed outpatients under
naturalistic conditions.
Methods: In this open-label post-marketing surveillance study in Germany,
patients were treated with escitalopram according to the package insert and
were observed at the start of treatment (baseline), at the end of the second
and 8 weeks of treatment. The main efficacy measures were the Clinical Global
Impression-Severity (CGI-S) scale and the short version of the Montgomery-
A˚sberg Depression Rating Scale (MADRS).
Results: A total of 11,760 patients were included, 99% of whom completed the
8-week treatment period. The majority of patients were moderately to markedly ill
based on their baseline CGI-S (mean 4.7) and MADRS total (mean 31.8) scores.
At baseline, 82.8% of the patients started with a daily dose of 10 mg, 12.1%
with 20 mg. At week 8, 64% of the patients were on a dose of 10 mg and 32.5%
on 20 mg/day escitalopram. During the course of the study, the patients showed
a clear improvement in their general severity of illness, as well as their severity
of depression, with scores of 3.1 and 12.5 on CGI-S and MADRS, respectively
(last-observation-carried-forward). Response (MADRS total score decreased by
at least 50%) was reached by 69.7% of patients, remission (MADRS total score
12) by 56.8% of patients at week 8. A sub-group analysis based on sex or age
(above or below 65 years) showed a good therapeutic effect in all subgroups. The
most frequent adverse reactions reported were nausea (1.7%), anxiety (0.7%),
and dizziness (0.6%).
Conclusions: The results of this large open-label study confirm under natu-
ralistic conditions the therapeutic efficacy and good tolerability of escitalopram
in the treatment of depression.
P03.118 DELIRIOUS EXTRAPYRAMIDAL REACTIONS AND
NEUROLEPTIC MALIGNANT SYNDROME
J. Lee. Graylands Hospital & University of Western Australia, Australia
Objectives: A neurotoxic syndrome with co-occurrence of delirium and various
extrapyramidal symptoms has been reported in association with antipsychotic
or antipsychotic-lithium therapy. It is unclear if the delirious extrapyramidal
syndrome is a distinct reaction to antipsychotics, a transitional stage in the
progression to neuroleptic malignant syndrome (NMS), or a variant of NMS. This
study intends to examine the clinical presentations of this neurotoxic syndrome
and explore its relationship with NMS.
Methods: 17 episodes (psychiatric diagnoses: 7 mania, 1 mixed mood state,
9 schizophrenia) with concurrent delirium and severe extrapyramidal symptoms
developed during treatment with antipsychotic medications were identified. They
fulfilled the DSM IV diagnostic criteria for delirium and neuroleptic-induced
movement disorders. No fever or prominent autonomic abnormality was noted
at the time of diagnosis. The severity of delirium was assessed using the
Delirium Rating Scale. They were managed as clinically indicated. Their progress
was closely monitored. The delirious extrapyramidal episodes were analysed
noting the various extrapyramidal syndromes, associated neurological symptoms,
laboratory findings, and progression of symptoms in these episodes.
Results: (a) Antipsychotic and concurrent medications: 12 conventional
antipsychotics (5 with concurrent lithium), 4 risperidone (1 with lithium), 1
olanzapine-lithium combination. (b) Extrapyramidal syndromes: 7 parkinso-
nian, 5 parkinsonian-dystonic, 1 parkinsonian-dystonic-akathisic, 1 dystonic,
1 dystonic-akathisic, 1 acute dyskinesic (choreoathetotic). (c) In 6 episodes
extrapyramidal symptoms first developed, followed by the emergence of delirium.
(d) In 5 episodes the delirious extrapyramidal syndrome progressed to NMS with
appearance of hyperthermia and autonomic disturbances. (e) Most of the non-
NMS episodes resolved promptly with discontinuation of the offending antipsy-
chotics. Two episodes that progressed to NMS were treated with amantadine or
bromocriptine with prompt resolution of symptoms.
Conclusion: The delirious extrapyramidal syndrome appears to be a distinct
neurotoxic reaction to antipsychotics. The observed progression in some cases
from extrapyramidal symptoms to a delirious extrapyramidal syndrome, and
from the delirious extrapyramidal syndrome to NMS supports the hypothesis
